Point-Counterpoint: Active Surveillance in the “Real World” Has Far More Risks Than We Appreciate

No AccessJournal of UrologyPoint of View1 Mar 2023Point-Counterpoint: Active Surveillance in the “Real World” Has Far More Risks Than We Appreciate Nathan Lawrentschuk Nathan LawrentschukNathan Lawrentschuk *Correspondence: EJ Whitten Prostate Cancer Centre, Epworth Healthcare, University of Melbourne ( E-mail Address: [email protected] https://orcid.org/0000-0001-8553-5618 Department of Surgery, Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Australia More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003133AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail "Point-Counterpoint: Active Surveillance in the “Real World” Has Far More Risks Than We Appreciate." The Journal of Urology, 209(3), pp. 504–505 References 1. . Gleason pattern 4: active surveillance no more. BJU Int. 2016; 117(6):856-857. Crossref, Medline, Google Scholar 2. . Sensible government decisions on funding for imaging can change practice and deliver better care for men with prostate cancer. BJU Int. 2022; 130(S1):4. Crossref, Google Scholar 3. . High prostate-specific membrane antigen (PSMA) positron emission tomography (PET) maximum standardized uptake value in men with PI-RADS score 4 or 5 confers a high probability of significant prostate cancer. BJU Int. 2022; 130(S3):5-7. Crossref, Medline, Google Scholar 4. . Large variation in conservative management of low-risk prostate cancer in Australia and New Zealand. BJU Int. 2022; 130(S1):17-19. Crossref, Medline, Google Scholar 5. . Low-grade prostate cancer should still be labelled cancer. BJU Int. 2022; 130(6):741-743. Crossref, Medline, Google Scholar 6. . Long-term outcomes following active surveillance of low-grade prostate cancer: a population-based study using a landmark approach. J Urol. 2023; 209(3):540-548. Link, Google Scholar Support: None. Conflict of Interest: The Author has no conflicts of interest to disclose. Ethics Statement: This study was deemed exempt from Institutional Review Board review. © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue 3March 2023Page: 504-505 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Nathan Lawrentschuk Department of Surgery, Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Australia *Correspondence: EJ Whitten Prostate Cancer Centre, Epworth Healthcare, University of Melbourne ( E-mail Address: [email protected] More articles by this author Expand All Support: None. Conflict of Interest: The Author has no conflicts of interest to disclose. Ethics Statement: This study was deemed exempt from Institutional Review Board review. Advertisement PDF downloadLoading ...